These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32941780)

  • 1. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
    Jiang S; Zhang X; Du L
    Expert Opin Ther Targets; 2021 Jun; 25(6):415-421. PubMed ID: 32941780
    [No Abstract]   [Full Text] [Related]  

  • 2. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
    Freidel MR; Armen RS
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals.
    Singh Y; Fuloria NK; Fuloria S; Subramaniyan V; Meenakshi DU; Chakravarthi S; Kumari U; Joshi N; Gupta G
    J Med Virol; 2021 Oct; 93(10):5726-5728. PubMed ID: 34232521
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets.
    Kamel NA; El Wakeel LM; Aboshanab KM
    Viral Immunol; 2021 Oct; 34(8):510-521. PubMed ID: 34018828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
    Santopolo S; Riccio A; Santoro MG
    Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
    Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
    J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of therapeutic monoclonal antibodies against SARS-CoV-2.
    Kumar S; Chandele A; Sharma A
    PLoS Pathog; 2021 Sep; 17(9):e1009885. PubMed ID: 34478455
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based development of human antibody cocktails against SARS-CoV-2.
    Wang N; Sun Y; Feng R; Wang Y; Guo Y; Zhang L; Deng YQ; Wang L; Cui Z; Cao L; Zhang YJ; Li W; Zhu FC; Qin CF; Wang X
    Cell Res; 2021 Jan; 31(1):101-103. PubMed ID: 33262454
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
    Li J; Wang P; Tracey KJ; Wang H
    Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics.
    Jiang X; Li D; Maghsoudloo M; Zhang X; Ma W; Fu J
    Drug Discov Today; 2024 Jul; 29(7):104026. PubMed ID: 38762086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    PLoS Pathog; 2024 Apr; 20(4):e1011680. PubMed ID: 38635853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipomoeassin-F inhibits the
    O'Keefe S; Roboti P; Duah KB; Zong G; Schneider H; Shi WQ; High S
    J Cell Sci; 2021 Feb; 134(4):. PubMed ID: 33468620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.
    Sun C; Zhang J; Wei J; Zheng X; Zhao X; Fang Z; Xu D; Yuan H; Liu Y
    PLoS One; 2021; 16(1):e0245975. PubMed ID: 33493227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.
    Sun Y; Wang L; Feng R; Wang N; Wang Y; Zhu D; Xing X; Yang P; Zhang Y; Li W; Wang X
    Cell Res; 2021 May; 31(5):597-600. PubMed ID: 33782529
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
    Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
    Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.